Association between <i>PD-1</i> and <i>PD-L1</i> Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies
A number of case-control studies regarding the association of the polymorphisms in the programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) genes with the risk of cancer have yielded inconsistent findings. Therefore, we have conducted a comprehensive, updated meta-analysis study...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/8/1150 |
| _version_ | 1797714802832834560 |
|---|---|
| author | Mohammad Hashemi Shima Karami Sahel Sarabandi Abdolkarim Moazeni-Roodi Andrzej Małecki Saeid Ghavami Emilia Wiechec |
| author_facet | Mohammad Hashemi Shima Karami Sahel Sarabandi Abdolkarim Moazeni-Roodi Andrzej Małecki Saeid Ghavami Emilia Wiechec |
| author_sort | Mohammad Hashemi |
| collection | DOAJ |
| description | A number of case-control studies regarding the association of the polymorphisms in the programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) genes with the risk of cancer have yielded inconsistent findings. Therefore, we have conducted a comprehensive, updated meta-analysis study to identify the impact of <i>PD-1</i> and <i>PD-L1</i> polymorphisms on overall cancer susceptibility. The findings revealed that <i>PD-1</i> rs2227981 and rs11568821 polymorphisms significantly decreased the overall cancer risk (Odds Ratio (OR) = 0.82, 95% CI = 0.68−0.99, <i>p</i> = 0.04, TT vs. CT+CC; OR = 0.79, 95% CI = 0.67−0.94, <i>p</i> = 0.006, AG vs. GG, and OR = 0.82, 95% CI = 0.70−0.96, <i>p</i> = 0.020, AG+AA vs. GG, respectively), while <i>PD-1</i> rs7421861 polymorphism significantly increased the risk of developing cancer (OR = 1.16, 95% CI = 1.02−1.33, <i>p</i> = 0.03, CT vs. TT). The <i>PD-L1</i> rs4143815 variant significantly decreased the risk of cancer in homozygous (OR = 0.62, 95% CI = 0.41−0.94, <i>p</i> = 0.02), dominant (OR = 0.70, 95% CI = 0.50−0.97, <i>p</i> = 0.03), recessive (OR = 0.76, 95% CI = 0.60−0.96, <i>p</i> = 0.02), and allele (OR = 0.78, 95% CI = 0.63−0.96, <i>p</i> = 0.02) genetic models. No significant association between rs2227982, rs36084323, rs10204525, and rs2890658 polymorphisms and overall cancer risk has been found. In conclusions, the results of this meta-analysis have revealed an association between <i>PD-1</i> rs2227981, rs11568821, rs7421861, as well as <i>PD-L1</i> rs4143815 polymorphisms and overall cancer susceptibility. |
| first_indexed | 2024-03-12T07:57:21Z |
| format | Article |
| id | doaj.art-edabe4d91d154fc8abc8eea66872e1f6 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T07:57:21Z |
| publishDate | 2019-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-edabe4d91d154fc8abc8eea66872e1f62023-09-02T20:06:36ZengMDPI AGCancers2072-66942019-08-01118115010.3390/cancers11081150cancers11081150Association between <i>PD-1</i> and <i>PD-L1</i> Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control StudiesMohammad Hashemi0Shima Karami1Sahel Sarabandi2Abdolkarim Moazeni-Roodi3Andrzej Małecki4Saeid Ghavami5Emilia Wiechec6Genetics of Non-communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan 9816743463, IranDepartment of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan 9816743175, IranDepartment of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan 9816743175, IranDepartment of Clinical Biochemistry, Iranshahr University of Medical Sciences, Iranshahr 9916643535, IranInstititute of Physiotherapy and Health Sciences, The Jerzy Kukuczka Academy of Physical Education in Katowice, 40-065 Katowice, PolandDepartment of Human Anatomy and Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, CanadaDepartment of Clinical and Experimental Medicine, Linköping University, 58183 Linköping, SwedenA number of case-control studies regarding the association of the polymorphisms in the programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) genes with the risk of cancer have yielded inconsistent findings. Therefore, we have conducted a comprehensive, updated meta-analysis study to identify the impact of <i>PD-1</i> and <i>PD-L1</i> polymorphisms on overall cancer susceptibility. The findings revealed that <i>PD-1</i> rs2227981 and rs11568821 polymorphisms significantly decreased the overall cancer risk (Odds Ratio (OR) = 0.82, 95% CI = 0.68−0.99, <i>p</i> = 0.04, TT vs. CT+CC; OR = 0.79, 95% CI = 0.67−0.94, <i>p</i> = 0.006, AG vs. GG, and OR = 0.82, 95% CI = 0.70−0.96, <i>p</i> = 0.020, AG+AA vs. GG, respectively), while <i>PD-1</i> rs7421861 polymorphism significantly increased the risk of developing cancer (OR = 1.16, 95% CI = 1.02−1.33, <i>p</i> = 0.03, CT vs. TT). The <i>PD-L1</i> rs4143815 variant significantly decreased the risk of cancer in homozygous (OR = 0.62, 95% CI = 0.41−0.94, <i>p</i> = 0.02), dominant (OR = 0.70, 95% CI = 0.50−0.97, <i>p</i> = 0.03), recessive (OR = 0.76, 95% CI = 0.60−0.96, <i>p</i> = 0.02), and allele (OR = 0.78, 95% CI = 0.63−0.96, <i>p</i> = 0.02) genetic models. No significant association between rs2227982, rs36084323, rs10204525, and rs2890658 polymorphisms and overall cancer risk has been found. In conclusions, the results of this meta-analysis have revealed an association between <i>PD-1</i> rs2227981, rs11568821, rs7421861, as well as <i>PD-L1</i> rs4143815 polymorphisms and overall cancer susceptibility.https://www.mdpi.com/2072-6694/11/8/1150apoptosis<i>PD-1</i><i>PD-L1</i>polymorphismcancermeta-analysis |
| spellingShingle | Mohammad Hashemi Shima Karami Sahel Sarabandi Abdolkarim Moazeni-Roodi Andrzej Małecki Saeid Ghavami Emilia Wiechec Association between <i>PD-1</i> and <i>PD-L1</i> Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies Cancers apoptosis <i>PD-1</i> <i>PD-L1</i> polymorphism cancer meta-analysis |
| title | Association between <i>PD-1</i> and <i>PD-L1</i> Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies |
| title_full | Association between <i>PD-1</i> and <i>PD-L1</i> Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies |
| title_fullStr | Association between <i>PD-1</i> and <i>PD-L1</i> Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies |
| title_full_unstemmed | Association between <i>PD-1</i> and <i>PD-L1</i> Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies |
| title_short | Association between <i>PD-1</i> and <i>PD-L1</i> Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies |
| title_sort | association between i pd 1 i and i pd l1 i polymorphisms and the risk of cancer a meta analysis of case control studies |
| topic | apoptosis <i>PD-1</i> <i>PD-L1</i> polymorphism cancer meta-analysis |
| url | https://www.mdpi.com/2072-6694/11/8/1150 |
| work_keys_str_mv | AT mohammadhashemi associationbetweenipd1iandipdl1ipolymorphismsandtheriskofcancerametaanalysisofcasecontrolstudies AT shimakarami associationbetweenipd1iandipdl1ipolymorphismsandtheriskofcancerametaanalysisofcasecontrolstudies AT sahelsarabandi associationbetweenipd1iandipdl1ipolymorphismsandtheriskofcancerametaanalysisofcasecontrolstudies AT abdolkarimmoazeniroodi associationbetweenipd1iandipdl1ipolymorphismsandtheriskofcancerametaanalysisofcasecontrolstudies AT andrzejmałecki associationbetweenipd1iandipdl1ipolymorphismsandtheriskofcancerametaanalysisofcasecontrolstudies AT saeidghavami associationbetweenipd1iandipdl1ipolymorphismsandtheriskofcancerametaanalysisofcasecontrolstudies AT emiliawiechec associationbetweenipd1iandipdl1ipolymorphismsandtheriskofcancerametaanalysisofcasecontrolstudies |